{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:55:17Z","timestamp":1774644917066,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jpba.2018.06.031","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T20:35:32Z","timestamp":1529440532000},"page":"376-385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies"],"prefix":"10.1016","volume":"158","author":[{"given":"Olga","family":"Maliszewska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Plenis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilona","family":"Ol\u0119dzka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Mi\u0119kus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Bie\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata Anna","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Adamkiewicz-Dro\u017cynska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"B\u0105czek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2018.06.031_bib0005","first-page":"887","article-title":"Induction of tumor-specific cytotoxicity and apoptosis by doxorubicin","volume":"25","author":"Suzuki","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jpba.2018.06.031_bib0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mpo.10052","article-title":"Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study","volume":"38","author":"Frost","year":"2002","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/j.jpba.2018.06.031_bib0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.4-1-34","article-title":"Rhabdomyosarcoma: an overview","volume":"4","author":"Dagher","year":"1999","journal-title":"Oncologist"},{"key":"10.1016\/j.jpba.2018.06.031_bib0020","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00280-016-3174-8","article-title":"Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a \u201cEuropean pediatric oncology off patents medicines consortium\u201d trial","volume":"78","author":"Krischke","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2018.06.031_bib0025","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin","volume":"57","author":"Gewirtz","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jpba.2018.06.031_bib0030","first-page":"84","article-title":"DNA torsion, and chromatin dynamics","volume":"1845","author":"Yang","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jpba.2018.06.031_bib0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.jpba.2018.06.031_bib0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2001.26431","article-title":"Anthracycline-induced cardiomyopathy","volume":"28","author":"Keefe","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.jpba.2018.06.031_bib0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1515\/cpp-2016-0006","article-title":"Adriamycin \u2013 efficacy and possible adverse effects","volume":"17","author":"Pedrycz","year":"2016","journal-title":"Curr. Probl. Psychiatry"},{"key":"10.1016\/j.jpba.2018.06.031_bib0050","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.1988.6.3.517","article-title":"Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans","volume":"6","author":"Mross","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2018.06.031_bib0055","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/08880010701451343","article-title":"Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient","volume":"24","author":"Ritzmo","year":"2007","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.jpba.2018.06.031_bib0060","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/01.cad.0000198911.98442.16","article-title":"Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia","volume":"17","author":"Palle","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jpba.2018.06.031_bib0065","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00280-001-0392-4","article-title":"Peak plasma concentrations of doxorubicin in children with acute lymphoblastic","volume":"49","author":"Hempel","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2018.06.031_bib0070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00001813-200002000-00010","article-title":"A comparative pharmacokinetic study of doxorubicin and 4\u2019-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure","volume":"11","author":"Eksborg","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jpba.2018.06.031_bib0075","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ejps.2010.07.015","article-title":"Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass","volume":"41","author":"Barpe","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2018.06.031_bib0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF00609693","article-title":"Pharmacokinetic study of IV infusions of adriamycin","volume":"28","author":"Eksborg","year":"1985","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2018.06.031_bib0085","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jpba.2015.04.007","article-title":"Simultaneous determination of doxorubicin and curcumin in rat plasma by LC\u2013MS\/MS and its application to pharmacokinetic study","volume":"111","author":"Ma","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.06.031_bib0090","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1080\/10826076.2012.678456","article-title":"Simultaneous determination of doxorubicin and irynotecan in conjunction with their major metabolites by ultra-high performance liquid chromatography","volume":"36","author":"Shaikh","year":"2013","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.jpba.2018.06.031_bib0095","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0378-4347(97)00610-5","article-title":"Simultaneous determination of epirubicin, doxorubicin and their principal metabolites in human plasma by high-performance liquid chromatography and electrochemical detection","volume":"707","author":"Ricciarello","year":"1998","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2018.06.031_bib0100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jchromb.2012.12.012","article-title":"Simultaneous measurement of doxorubicin and reduced metabolite doxorubicinol by UHPLC\u2013MS\/MS in human plasma of HCC patients treated with TACE","volume":"915\u2013916","author":"Sottani","year":"2013","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2018.06.031_bib0105","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/elps.201300237","article-title":"Determination of doxorubicin in plasma by using CE coupled with in-column tapered optic-fiber light-emitting diode induced fluorescence detection","volume":"35","author":"Yang","year":"2014","journal-title":"Electrophoresis"},{"key":"10.1016\/j.jpba.2018.06.031_bib0110","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1002\/1522-2683(200108)22:13<2782::AID-ELPS2782>3.0.CO;2-I","article-title":"Determination of anthracycline antibiotics doxorubicin and daunorubicin by capillary electrophoresis with UV absorption detection","volume":"22","author":"Gavenda","year":"2001","journal-title":"Electrophoresis"},{"key":"10.1016\/j.jpba.2018.06.031_bib0115","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0731-7085(95)01301-Z","volume":"13","author":"Fraier","year":"1995","journal-title":"J. Pharm. Biomed."},{"key":"10.1016\/j.jpba.2018.06.031_bib0120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jchromb.2014.02.034","article-title":"Validation and clinical evaluation of a UHPLC method with fluorescence detector for plasma quantification of doxorubicin and doxorubicinol in haematological patients","volume":"955\u2013956","author":"P\u00e9rez-Blanco","year":"2014","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2018.06.031_bib0125","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/rcm.3657","article-title":"Simultaneous determination of cyclophosphamide, ifosfamide, doxorubicin, epirubicin and daunorubicin in human urine using high-performance liquid chromatography\/electrospray ionization tandem mass spectrometry: bioanalytical method validation","volume":"22","author":"Sottani","year":"2008","journal-title":"Rapid Commun. Mass. Spectrom."},{"key":"10.1016\/j.jpba.2018.06.031_bib0130","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/rcm.1642","article-title":"Trace determination of anthracyclines in urine: a new high-performance liquid chromatography\/tandem mass spectrometry method for assessing exposure of hospital personnel","volume":"18","author":"Sottani","year":"2004","journal-title":"Rapid Commun. Mass. Spectrom."},{"key":"10.1016\/j.jpba.2018.06.031_bib0135","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0731-7085(02)00442-9","article-title":"Determination of doxorubicin and its metabolites in rat serum and bile by LC: application to preclinical pharmacokinetic studies","volume":"30","author":"Zhou","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.06.031_bib0140","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jpba.2006.06.032","article-title":"Determination of doxorubicin in rabbit ocular tissues and pharmacokinetics after intravitreal injection of a single dose of doxorubicin-loaded poly-\u03b2-hydroxybutyrate microspheres","volume":"43","author":"Hu","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.06.031_bib0145","series-title":"Guideline on Bioanalytical Method Validation","year":"2011"},{"key":"10.1016\/j.jpba.2018.06.031_bib0150","series-title":"Guidance for Industry Bioanalytical Method Validation","year":"2001"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518308732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518308732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T18:59:57Z","timestamp":1604429997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708518308732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":30,"alternative-id":["S0731708518308732"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2018.06.031","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2018.06.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}